Varian Announces CEO Succession Plan

Dow Wilson to Retire as CEO; Will Serve as Special Advisor to the Combined Company

PALO ALTO, Calif., March 2, 2021 /PRNewswire/ — Varian today announced that Chief Executive Officer Dow Wilson, after more than 16 years with the Company, will retire upon the successful completion of the proposed combination of Varian and Siemens Healthineers AG (SMMNY) (Frankfurt: SHL). Wilson will be succeeded by Chris Toth, President and Chief Operating Officer of Varian, who will become CEO of the Varian business segment of Siemens Healthineers upon the transaction close. Toth will report directly to Dr. Bernd Montag, Chief Executive Officer of Siemens Healthineers.

In connection with the completion of the transaction, which is expected to occur in the first half of calendar year 2021, and to support a seamless integration of Varian into Siemens Healthineers, Wilson has agreed to serve as a special advisor to Siemens Healthineers.

“On behalf of the Board, I want to thank Dow for his exceptional leadership and many contributions to Varian,” said Andrew Eckert, Chairman of the Board. “Since his appointment as CEO in 2012, Dow has led Varian’s efforts to define a new era in cancer care. In addition to significantly extending the Company’s market leadership and innovation in radiation therapy, he oversaw Varian’s progress in bringing artificial intelligence, machine learning and cloud solutions to the fight against cancer. Through this strategic transformation, Varian has achieved double-digit growth and created 4,000 jobs over the last five years, and importantly, has enabled more successful outcomes for millions of patients worldwide.”

“It has been a privilege to serve Varian as CEO for nearly a decade,” said Wilson. “We have made incredible advances in the fight against cancer, and our transformational combination with Siemen Healthineers will bring us even closer to achieving our vision of a world without fear of cancer. Working alongside such a talented, dedicated team has been the highlight of my career, and I am confident that under Chris’ leadership, Varian will continue to increase its patient impact and build on the strong foundation we have established together. I will always be an ardent supporter of Varian, and look forward to following along from the sidelines and seeing all that this team accomplishes in the years to come.”

“I’m honored to lead Varian as we enter this new exciting chapter with Siemens Healthineers,” said Toth. “It’s incredible to see how Varian has evolved and grown since I first joined over 20 years ago – all while staying true to our relentless belief that we can beat cancer. As we move forward, I’m confident that the passion and unwavering commitment to Varian’s mission that Dow has inspired among the entire team will continue to propel our company to even greater success in the future.”

About Varian
At Varian, we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 10,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Investor Relations Contact
Anshul Maheshwari
Vice President, Treasury (TSRMF) and Investor Relations
+1 (650) 424-6081
investors@varian.com

Press Contact
Kathy Conner
Vice President, Global Corporate Marketing
+1 (650) 424-5695
kathy.conner@varian.com

SOURCE Varian

Tags: